Telethon Kids Institute   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Perth Australia (1990)

Organization Overview

First Clinical Trial
2012
NCT01270074
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Telethon Kids Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Bronchiectasis (Phase 3)

Bronchiolitis (Phase 2)

Communicable Diseases (Phase 1)

Coronavirus Infections (Phase 3)

Cystic Fibrosis (Phase 3)

Emergencies (Phase 2)

Fibrosis (Phase 3)

Gastroenteritis (Phase 4)

Gram-Positive Bacterial Infections (Phase 1)

Hemolysis (Phase 1)

Infections (Phase 1)

Pharyngitis (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Streptococcal Infections (Phase 1)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 15